We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.65%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.58B
AUM Growth
-$133M
Cap. Flow
-$75.4M
Cap. Flow %
-1.64%
Top 10 Hldgs %
23.53%
Holding
172
New
18
Increased
60
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$102M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$50.7M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$48.4M
4
CGEM icon
Cullinan Oncology
CGEM
+$43.7M
5
AZN icon
AstraZeneca
AZN
+$32.7M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$58.7M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
UNH icon
UnitedHealth
UNH
+$45M
4
CNC icon
Centene
CNC
+$43.8M
5
IMVT icon
Immunovant
IMVT
+$41.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Consumer Staples 1.75%
3 Industrials 0.62%
4 Financials 0.12%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$55.4M 1.21%
323,647
-49,505
-13% -$9.8M
TFX icon
27
Teleflex
TFX
$5.95B
$54M 1.18%
130,000
– –
BOLT icon
28
Bolt Biotherapeutics
BOLT
$7.78M
$51.3M 1.12%
+77,962
New +$50.7M
RARE icon
29
Ultragenyx Pharmaceutical
RARE
$2.64B
$51.2M 1.12%
450,000
-116,500
-21% -$15.9M
EW icon
30
Edwards Lifesciences
EW
$53.2B
$48.7M 1.06%
582,000
– –
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
$44.9M 0.98%
111,005
+28,458
+34% +$13.8M
CGEM icon
32
Cullinan Oncology
CGEM
$1.15B
$44.8M 0.98%
+1,075,912
New +$43.7M
KRTX
33
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$44.3M 0.97%
368,764
+124,814
+51% +$14.1M
PHR icon
34
Phreesia
PHR
$767M
$44.3M 0.97%
850,000
– –
EAR
35
DELISTED
Eargo, Inc. Common Stock
EAR
$42.5M 0.93%
42,584
-2,416
-5% -$2.76M
ALNY icon
36
Alnylam Pharmaceuticals
ALNY
$29.1B
$42.4M 0.92%
300,000
-35,000
-10% -$5.27M
CVET
37
DELISTED
Covetrus, Inc. Common Stock
CVET
$42M 0.92%
1,400,000
+115,000
+9% +$3.92M
ARVN icon
38
Arvinas
ARVN
$581M
$41.1M 0.9%
621,800
-124,200
-17% -$9.5M
EHC icon
39
Encompass Health
EHC
$12.4B
$41M 0.89%
628,500
– –
ACHC icon
40
Acadia Healthcare
ACHC
$2.96B
$40M 0.87%
700,000
– –
PEN icon
41
Penumbra
PEN
$12.9B
$39.9M 0.87%
147,500
-11,500
-7% -$2.97M
TVTX icon
42
Travere Therapeutics
TVTX
$5.75B
$36.8M 0.8%
1,475,564
+454,564
+45% +$12.6M
HCAT icon
43
Health Catalyst
HCAT
$131M
$36.7M 0.8%
785,000
– –
ALLK
44
DELISTED
Allakos
ALLK
$35.1M 0.77%
305,706
-35,794
-10% -$4.52M
SGEN
45
DELISTED
Seagen Inc. Common Stock
SGEN
$34.7M 0.76%
250,000
– –
ARDX icon
46
Ardelyx
ARDX
$974M
$34.3M 0.75%
5,176,561
+28,449
+0.6% +$195K
AZN icon
47
AstraZeneca
AZN
$250B
$32.3M 0.71%
+325,000
New +$32.7M
BIIB icon
48
Biogen
BIIB
$30.5B
$31.8M 0.69%
113,500
+13,500
+14% +$3.64M
BSX icon
49
Boston Scientific
BSX
$73.5B
$30.9M 0.67%
800,000
– –
GH icon
50
Guardant Health
GH
$22.8B
$30.5M 0.67%
200,000
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Rock Springs Capital Management held 172 positions worth $4.58B, down 2.8% from $4.72B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q1 2021 filing shows 18 new, 60 increased, 32 reduced and 21 closed positions. Its largest new stake was Immunocore: 2,292,285 shares worth $97.6M. The largest sale was Neurocrine Biosciences, an estimated $58.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2021 buy was Immunocore: 2,292,285 shares worth $97.6M.
  • Rock Springs Capital Management added most to Five Prime Therapeutics, Inc. in Q1 2021, an estimated $48.4M increase.
  • Rock Springs Capital Management's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $58.7M.
  • Rock Springs Capital Management fully exited Alexion Pharmaceuticals in Q1 2021, selling an estimated $47.9M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.58B portfolio in Q1 2021.
  • Rock Springs Capital Management opened 18 new positions and closed 21 in Q1 2021.
  • Rock Springs Capital Management's portfolio value fell 2.8% quarter-over-quarter to $4.58B.

Based on Rock Springs Capital Management's 13F filing for Q1 2021, filed 17 May 2021.